WuXi Biologics: Net profit is expected to grow by 46.3% to 4.908 billion yuan in 2025, with significant growth in both the biopharmaceutical and XDC business segments.

On March 24, WuXi Biologics released its annual performance announcement for the year ending December 31, 2025. The company’s revenue for 2025 was 21.79 billion yuan, an increase of 16.7% year-on-year; gross profit was 10.019 billion yuan, an increase of 30.9% year-on-year, with a gross margin rising to 46.0%; net profit attributable to the parent company was 4.908 billion yuan, a year-on-year increase of 46.3%.

In the management discussion and analysis section, the company mentioned significant business growth driven by its integrated CRDMO platform and the “Follow and Win Molecules” strategy, adding 209 comprehensive projects, bringing the total to 945. Late-stage clinical and commercial production projects also increased to 74 and 25, respectively.

In the notes to the financial statements, the cost of sales rose from 11.025 billion yuan to 11.772 billion yuan, an increase of 6.8%. Overall, the company achieved significant growth in both its biopharmaceutical and XDC business segments, with external sales in the biopharmaceutical segment amounting to 15.89 billion yuan and external sales in XDC reaching 5.9 billion yuan, demonstrating the company’s strong performance and competitiveness in the market.

(WuXi Biologics Announcement)

(Editor: Yang Yan, Lin Chen)

Keywords:

                                                            Medical